A detailed history of Tower Research Capital LLC (Trc) transactions in Vera Therapeutics, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 240 shares of VERA stock, worth $11,594. This represents 0.0% of its overall portfolio holdings.

Number of Shares
240
Previous 5,907 95.94%
Holding current value
$11,594
Previous $213,000 95.31%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$34.09 - $46.71 $193,188 - $264,705
-5,667 Reduced 95.94%
240 $10,000
Q2 2024

Aug 13, 2024

BUY
$33.72 - $48.82 $183,537 - $265,727
5,443 Added 1173.06%
5,907 $213,000
Q1 2024

May 15, 2024

SELL
$14.91 - $49.14 $116,760 - $384,815
-7,831 Reduced 94.41%
464 $20,000
Q4 2023

Feb 13, 2024

BUY
$9.29 - $16.0 $55,331 - $95,296
5,956 Added 254.64%
8,295 $127,000
Q3 2023

Nov 14, 2023

BUY
$13.71 - $19.64 $5,634 - $8,072
411 Added 21.32%
2,339 $32,000
Q2 2023

Aug 14, 2023

SELL
$6.11 - $17.83 $17,755 - $51,813
-2,906 Reduced 60.12%
1,928 $30,000
Q1 2023

May 09, 2023

BUY
$5.41 - $18.3 $23,279 - $78,744
4,303 Added 810.36%
4,834 $38,000
Q4 2022

Feb 10, 2023

SELL
$15.74 - $22.19 $15,802 - $22,278
-1,004 Reduced 65.41%
531 $10,000
Q3 2022

Nov 10, 2022

BUY
$13.27 - $22.31 $1,393 - $2,342
105 Added 7.34%
1,535 $33,000
Q2 2022

Aug 15, 2022

BUY
$12.82 - $23.4 $15,422 - $28,150
1,203 Added 529.96%
1,430 $19,000
Q1 2022

May 12, 2022

SELL
$17.8 - $28.06 $5,535 - $8,726
-311 Reduced 57.81%
227 $5,000
Q4 2021

Feb 14, 2022

SELL
$15.01 - $35.8 $1,005 - $2,398
-67 Reduced 11.07%
538 $14,000
Q3 2021

Nov 15, 2021

BUY
$13.71 - $30.6 $8,294 - $18,513
605 New
605 $10,000

Others Institutions Holding VERA

About Vera Therapeutics, Inc.


  • Ticker VERA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 27,042,300
  • Market Cap $1.31B
  • Description
  • Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases in the United States. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase IIb clinical trial for patients with ...
More about VERA
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.